Vynca
United States
- Palo Alto, CA
- 31/01/2022
- Series C
- $30,000,000
Vynca enables high-quality, person-centered, goal-concordant care that reflects individuals’ wishes with their serious illness management platform that incorporates virtual palliative care services, advance care planning, care coordination, symptom management, whole-person care and provider engagement. The company’s comprehensive solution set empowers providers, individuals and their families to have meaningful conversations about future care preferences supported by a broad range of serious illness management services offered from a single point of trust to deliver successful value-based arrangements to healthcare organizations. With this approach, Vynca is able to ensure that personalized end-of-life care is available for every individual, every time.
- Industry Hospital & Health Care
- Website https://vyncahealth.com/
- LinkedIn https://www.linkedin.com/company/vynca/
ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)